Developer docs
API playgroundTry for free, no card

Search company profiles

Pharma Solutions at IFF

Full company profile

uuid003i2l6

Namestring
Pharma Solutions at IFF
Legal namestring
IFF Pharma Solutions
Websiteurl
pharma.iff.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Pharma Solutions at IFF is a global provider of polymer-based pharmaceutical excipients, dietary supplement ingredients, and biomedical biopolymers, now operating as part of Roquette Frères S.A.'s Health & Pharma Solutions division following Roquette's May 2025 acquisition of the business from International Flavors & Fragrances (IFF). The company's core technology platform centers on specialized polymers including cellulosics (METHOCEL HPMC), polyethylene oxide polymers (POLYOX), high-quality biopolymers (METHONOVA, NovaMatrix), and starch-derived alginate technologies, serving pharmaceutical manufacturers across the entire drug development pipeline, dietary supplement companies seeking clean-label formats, and biomedical and life science firms requiring specialized biopolymer solutions.

The business operates a B2B enterprise sales model through direct sales teams supported by global customer support, targeting large pharmaceutical manufacturers, nutraceutical producers, and biotechnology companies worldwide. Revenue is generated through transaction-based sale of specialized excipients and ingredients, with quote-based pricing for pharmaceutical-grade materials. Key product lines include POLYOX polyethylene oxide polymers for controlled release applications, METHOCEL HPMC including a low nitrite variant addressing nitrosamine mitigation concerns, METHONOVA biomedical solutions, and NovaMatrix biopolymers for life science applications. The company's competitive position is anchored in proprietary technology, global manufacturing scale, regulatory compliance expertise, and scientific know-how demonstrated through thought leadership platforms including POLYOX Academy and Controlled Release resources.

Recent strategic activity includes the establishment of a new Pharmaceutical Innovation Center in Latin America (October 2025), the launch of DS 700 water-resistant capsule technology and three new alginate-based formulations (April 2026), and recognition with the 2025 NIE New Ingredient Award for Low Nitrite METHOCEL HPMC. The business serves a global customer base across pharmaceutical manufacturing, dietary supplements, and biomedical and biologicals segments, with particular strength in excipient innovation for controlled release and drug delivery applications.

Short descriptiontext

Pharma Solutions at IFF, now part of Roquette Frères S.A., is a global provider of polymer-based pharmaceutical excipients, dietary supplement ingredients, and biomedical biopolymers, serving pharmaceutical manufacturers, nutraceutical companies, and life science firms worldwide through proprietary brands including POLYOX, METHOCEL, METHONOVA, and NovaMatrix.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmaceutical excipients, drug delivery systems, cellulose derivatives, controlled release polymers, biopolymer solutions
Industry3 codes
1Medical & Food-Contact Specialty Compounds
CodeIMANABAKPrimaryYes
2Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT)
CodeIMAEAOAAPrimaryNo
3Bio-Based & Biodegradable Compounds (PLA/PHA/Starch Blends)
CodeIMANABAFPrimaryNo
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
  • Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing3252
SIC code3 codes
  • Medicinal Chemicals & Botanical Products2833
  • Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)2820
  • Industrial Organic Chemicals2860
Product category
Pharmaceutical Excipients
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Excipients and Ingredients
TypeTransaction Fee
Description

Sale of specialized pharmaceutical excipients including cellulosics, biopolymers, and synthetic polymers to pharmaceutical manufacturers for drug formulation and manufacturing

pharma.roquette.com
2Biomedical and Biotechnology Solutions
TypeTransaction Fee
Description

Supply of biopolymers and specialized materials for biomedical research, drug delivery systems, and life science applications

pharma.roquette.com
3Dietary Supplement Ingredients
TypeTransaction Fee
Description

Provision of clean-label ingredients and formulations for dietary supplements, nutraceuticals, and wellness products

pharma.roquette.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1METHONOVA™
Description

Products for biomedical and biological applications

pharma.roquette.com
+6 more records
Core offering1 text field

Pharma Solutions at IFF manufactures and supplies pharmaceutical excipients and specialty polymer ingredients — including cellulosics, seaweed extracts, ultrapure biopolymers, and specialized synthetic polymers — for use in drug formulation, controlled release drug delivery, dietary supplement manufacturing, and biomedical/life science applications. Its proprietary product portfolio encompasses POLYOX™ polyethylene oxide polymers, METHOCEL™ HPMC, METHONOVA™ biopolymers, NovaMatrix® and NovaMatrix-3D™ platforms, starch-derived alginate technologies, and the DS 700 water-resistant capsule.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • DS 700 water-resistant capsule delivers nearly 100% water resistance for long-lasting applications
Product overview1 text field

Roquette Health & Pharma Solutions (formerly IFF Pharma Solutions, acquired May 2025) operates as a multi-segment platform providing sustainable polymer-based solutions across three core areas: Pharmaceuticals (cellulosics, seaweed extracts, biopolymers, synthetic polymers), Dietary Supplements (clean-label formats like gummies and softgels), and Biomedical & Biologicals (biopolymers via METHONOVA™, NovaMatrix®, NovaMatrix-3D™). The portfolio includes key product lines such as POLYOX™ polyethylene oxide polymers and METHOCEL HPMC for controlled release applications. Recent innovations include DS 700 water-resistant capsules and alginate-based technologies derived from starch. The company also offers thought leadership platforms including POLYOX Academy, Controlled Release resources, and Excipient Insights.

Product and service9 records
1Pharmaceutical Excipients Portfolio
CategoryPharmaceutical Excipients
Description

Sustainable cellulosics, seaweed extracts, ultrapure biopolymers, and specialized synthetic polymers for pharmaceutical manufacturers, supported by polymer expertise across the entire drug development pipeline.

2POLYOX™ Polyethylene Oxide Polymers
CategoryPolymer Excipients
Description

Polyethylene oxide polymers for pharmaceutical applications, used in controlled release and other drug delivery capabilities, backed by the POLYOX Academy thought leadership platform.

3METHOCEL™ HPMC
CategoryCellulosic Excipients
Description

Hydroxypropyl methylcellulose polymer for controlled release pharmaceutical applications, including a Low Nitrite variant awarded the 2025 NIE New Ingredient Award.

4Dietary Supplement Ingredients
CategoryNutraceutical Ingredients
Description

Clean-label and great-tasting dietary supplement formats including gummies and plant-based softgels, supported by technical expertise and market understanding throughout nutraceutical formulation and manufacturing.

5METHONOVA™ Biomedical Products
CategoryBiomedical Biopolymers
Description

Biomedical and biological products portfolio powered by high-quality biopolymers for specialized biotechnology applications.

6NovaMatrix® Biopolymers
CategoryBiomedical Biopolymers
Description

High-quality biopolymer products for biomedical and life science applications, supported by comprehensive biotechnology solutions and polymer expertise.

7NovaMatrix-3D™
CategoryBiomedical 3D Matrix Applications
Description

Advanced 3D biomedical and biological applications powered by biopolymer technology.

8DS 700 Water-Resistant Capsule
CategoryCapsule Technology
Description

Water-resistant capsule with nearly 100% resistance designed for long-lasting beauty and pharmaceutical applications.

9Alginate-Based Formulations
CategoryAlginate-Based Polymers
Description

Starch-derived alginate-based formulations offering enhanced rheology and viscosity impacts for cosmetic and pharmaceutical applications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty chemicals company with a Healthcare & Life Sciences division producing pharmaceutical excipients, drug delivery polymers (e.g., EUDRAGIT), and APIs. Overlaps directly with the controlled-release and specialty polymer franchise of Roquette Health & Pharma Solutions.

TypeDirect peer
Description

Pharmaceutical excipient and drug delivery company specializing in antacid actives, vaccine adjuvants, and patient-friendly dosage formats. Comparable niche-specialty positioning targeting the same pharma manufacturers and formulation challenges.

TypeBroad incumbent
Description

DuPont's specialty products business includes cellulosics and pharmaceutical-grade polymers (e.g., ETHOCEL). Competes with IFF/Roquette in pharmaceutical excipients and shares heritage in cellulosic polymer technology.

TypeEmerging player
Description

Specialty food and beverage ingredients company expanding into pharma-grade and clean-label excipients. Adjacent competitor in the dietary supplement and nutraceutical excipient space where Roquette Health & Pharma Solutions operates.

TypeBroad incumbent
Description

Global chemical major with a broad pharmaceutical excipients and active ingredient portfolio (e.g., Kollidon, Kolliphor, PVP-based systems). Competes with Roquette Health & Pharma Solutions across multiple polymer excipient categories and serves the same large pharma customers.

TypeEmerging player
Description

Specialty ingredient company with growing pharma and nutraceutical excipient lines (e.g., starch-based, clean-label ingredients). Increasingly comparable to Roquette Health & Pharma Solutions' dietary supplement and starch-derived alginate platforms.

TypeDirect peer
Description

Specialty excipient and coating systems company focused on oral solid dose pharmaceutical and nutraceutical applications. Closely competes with METHOCEL HPMC-based coatings, controlled-release platforms, and dietary supplement clean-label formats offered by Roquette Health & Pharma Solutions.

TypeDirect peer
Description

Specialty excipient manufacturer focused on cellulose-based excipients (MCC, microcrystalline cellulose, croscarmellose sodium, HPMC). Direct competitor in the cellulosic excipient franchise that underpins Roquette Health & Pharma Solutions' pharmaceutical business.

TypeBroad incumbent
Description

Life science arm of Merck KGaA supplying pharmaceutical excipients, bioprocessing materials, and lab solutions. Overlaps with Roquette Health & Pharma Solutions on the biomedical/biologics side (METHONOVA, NovaMatrix biopolymers) and broader excipient supply.

TypeDirect peer
Description

Specialty chemical company with a significant pharmaceutical excipients and oral solid dose franchise (e.g., cellulosics, coating systems, controlled-release polymers). Direct competitor to IFF/Roquette's HPMC and POLYOX-based offerings for pharma formulation.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharma Solutions at IFF

Pharmaceutical Excipientspharma.iff.com

Pharma Solutions at IFF, now part of Roquette Frères S.A., is a global provider of polymer-based pharmaceutical excipients, dietary supplement ingredients, and biomedical biopolymers, serving pharmaceutical manufacturers, nutraceutical companies, and life science firms worldwide through proprietary brands including POLYOX, METHOCEL, METHONOVA, and NovaMatrix.

What Pharma Solutions at IFF does

Pharma Solutions at IFF is a global provider of polymer-based pharmaceutical excipients, dietary supplement ingredients, and biomedical biopolymers, now operating as part of Roquette Frères S.A.'s Health & Pharma Solutions division following Roquette's May 2025 acquisition of the business from International Flavors & Fragrances (IFF). The company's core technology platform centers on specialized polymers including cellulosics (METHOCEL HPMC), polyethylene oxide polymers (POLYOX), high-quality biopolymers (METHONOVA, NovaMatrix), and starch-derived alginate technologies, serving pharmaceutical manufacturers across the entire drug development pipeline, dietary supplement companies seeking clean-label formats, and biomedical and life science firms requiring specialized biopolymer solutions.

The business operates a B2B enterprise sales model through direct sales teams supported by global customer support, targeting large pharmaceutical manufacturers, nutraceutical producers, and biotechnology companies worldwide. Revenue is generated through transaction-based sale of specialized excipients and ingredients, with quote-based pricing for pharmaceutical-grade materials. Key product lines include POLYOX polyethylene oxide polymers for controlled release applications, METHOCEL HPMC including a low nitrite variant addressing nitrosamine mitigation concerns, METHONOVA biomedical solutions, and NovaMatrix biopolymers for life science applications. The company's competitive position is anchored in proprietary technology, global manufacturing scale, regulatory compliance expertise, and scientific know-how demonstrated through thought leadership platforms including POLYOX Academy and Controlled Release resources.

Recent strategic activity includes the establishment of a new Pharmaceutical Innovation Center in Latin America (October 2025), the launch of DS 700 water-resistant capsule technology and three new alginate-based formulations (April 2026), and recognition with the 2025 NIE New Ingredient Award for Low Nitrite METHOCEL HPMC. The business serves a global customer base across pharmaceutical manufacturing, dietary supplements, and biomedical and biologicals segments, with particular strength in excipient innovation for controlled release and drug delivery applications.

Pharma Solutions at IFF firmographics

Firmographics
Name
Pharma Solutions at IFF
Legal name
IFF Pharma Solutions
Website
https://pharma.iff.com
Company type
Private
Operating status
Acquired
Headcount range
5,001–10,000 employees
Short description
Pharma Solutions at IFF, now part of Roquette Frères S.A., is a global provider of polymer-based pharmaceutical excipients, dietary supplement ingredients, and biomedical biopolymers, serving pharmaceutical manufacturers, nutraceutical companies, and life science firms worldwide through proprietary brands including POLYOX, METHOCEL, METHONOVA, and NovaMatrix.
Ownership category
akta.pro rank

Pharma Solutions at IFF industry classification

Industry
Product category
Pharmaceutical Excipients
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252)
SIC
Medicinal Chemicals & Botanical Products (2833), Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820), Industrial Organic Chemicals (2860)
akta.pro primary industry
Medical & Food-Contact Specialty Compounds (IMANABAK)
akta.pro secondary industries
Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT) (IMAEAOAA), Bio-Based & Biodegradable Compounds (PLA/PHA/Starch Blends) (IMANABAF)

Keywords

  • Pharmaceutical excipients
  • Drug delivery systems
  • Cellulose derivatives
  • Controlled release polymers
  • Biopolymer solutions

Where Pharma Solutions at IFF is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Pharma Solutions at IFF business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Excipients and Ingredients: Sale of specialized pharmaceutical excipients including cellulosics, biopolymers, and synthetic polymers to pharmaceutical manufacturers for drug formulation and manufacturing
  2. Biomedical and Biotechnology Solutions: Supply of biopolymers and specialized materials for biomedical research, drug delivery systems, and life science applications
  3. Dietary Supplement Ingredients: Provision of clean-label ingredients and formulations for dietary supplements, nutraceuticals, and wellness products

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Pharma Solutions at IFF product offering

Product offering

Core offering

Pharma Solutions at IFF manufactures and supplies pharmaceutical excipients and specialty polymer ingredients — including cellulosics, seaweed extracts, ultrapure biopolymers, and specialized synthetic polymers — for use in drug formulation, controlled release drug delivery, dietary supplement manufacturing, and biomedical/life science applications. Its proprietary product portfolio encompasses POLYOX™ polyethylene oxide polymers, METHOCEL™ HPMC, METHONOVA™ biopolymers, NovaMatrix® and NovaMatrix-3D™ platforms, starch-derived alginate technologies, and the DS 700 water-resistant capsule.

Product overview

Roquette Health & Pharma Solutions (formerly IFF Pharma Solutions, acquired May 2025) operates as a multi-segment platform providing sustainable polymer-based solutions across three core areas: Pharmaceuticals (cellulosics, seaweed extracts, biopolymers, synthetic polymers), Dietary Supplements (clean-label formats like gummies and softgels), and Biomedical & Biologicals (biopolymers via METHONOVA™, NovaMatrix®, NovaMatrix-3D™). The portfolio includes key product lines such as POLYOX™ polyethylene oxide polymers and METHOCEL HPMC for controlled release applications. Recent innovations include DS 700 water-resistant capsules and alginate-based technologies derived from starch. The company also offers thought leadership platforms including POLYOX Academy, Controlled Release resources, and Excipient Insights.

Differentiator

Problem solved

Functional benefit

Brands

  • METHONOVA™: Products for biomedical and biological applications
  • NovaMatrix®
  • NovaMatrix-3D™
  • POLYOX™
  • METHOCEL™
  • Roquette Beauté
  • AnswerCenter

Products and services

  • Pharmaceutical Excipients Portfolio Sustainable cellulosics, seaweed extracts, ultrapure biopolymers, and specialized synthetic polymers for pharmaceutical manufacturers, supported by polymer expertise across the entire drug development pipeline.
  • POLYOX™ Polyethylene Oxide Polymers Polyethylene oxide polymers for pharmaceutical applications, used in controlled release and other drug delivery capabilities, backed by the POLYOX Academy thought leadership platform.
  • METHOCEL™ HPMC Hydroxypropyl methylcellulose polymer for controlled release pharmaceutical applications, including a Low Nitrite variant awarded the 2025 NIE New Ingredient Award.
  • Dietary Supplement Ingredients Clean-label and great-tasting dietary supplement formats including gummies and plant-based softgels, supported by technical expertise and market understanding throughout nutraceutical formulation and manufacturing.
  • METHONOVA™ Biomedical Products Biomedical and biological products portfolio powered by high-quality biopolymers for specialized biotechnology applications.
  • NovaMatrix® Biopolymers High-quality biopolymer products for biomedical and life science applications, supported by comprehensive biotechnology solutions and polymer expertise.
  • NovaMatrix-3D™ Advanced 3D biomedical and biological applications powered by biopolymer technology.
  • DS 700 Water-Resistant Capsule Water-resistant capsule with nearly 100% resistance designed for long-lasting beauty and pharmaceutical applications.
  • Alginate-Based Formulations Starch-derived alginate-based formulations offering enhanced rheology and viscosity impacts for cosmetic and pharmaceutical applications.

Quantifiable outcome

  • DS 700 water-resistant capsule delivers nearly 100% water resistance for long-lasting applications

Companies that use Pharma Solutions at IFF

Customer profile

Segments3 records

Ideal customer profiles3 records

Pharma Solutions at IFF technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Pharma Solutions at IFF partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Pharma Solutions at IFF competitors and assessment

Company assessment

Broad incumbents

  • Evonik Industries: Specialty chemicals company with a Healthcare & Life Sciences division producing pharmaceutical excipients, drug delivery polymers (e.g., EUDRAGIT), and APIs. Overlaps directly with the controlled-release and specialty polymer franchise of Roquette Health & Pharma Solutions.
  • DuPont Nutrition & Biosciences (now part of IFF, but specialty excipient operations continue under separate entities): DuPont's specialty products business includes cellulosics and pharmaceutical-grade polymers (e.g., ETHOCEL). Competes with IFF/Roquette in pharmaceutical excipients and shares heritage in cellulosic polymer technology.
  • BASF SE: Global chemical major with a broad pharmaceutical excipients and active ingredient portfolio (e.g., Kollidon, Kolliphor, PVP-based systems). Competes with Roquette Health & Pharma Solutions across multiple polymer excipient categories and serves the same large pharma customers.
  • Merck KGaA Life Science (MilliporeSigma): Life science arm of Merck KGaA supplying pharmaceutical excipients, bioprocessing materials, and lab solutions. Overlaps with Roquette Health & Pharma Solutions on the biomedical/biologics side (METHONOVA, NovaMatrix biopolymers) and broader excipient supply.

Direct peers

  • SPI Pharma: Pharmaceutical excipient and drug delivery company specializing in antacid actives, vaccine adjuvants, and patient-friendly dosage formats. Comparable niche-specialty positioning targeting the same pharma manufacturers and formulation challenges.
  • Colorcon: Specialty excipient and coating systems company focused on oral solid dose pharmaceutical and nutraceutical applications. Closely competes with METHOCEL HPMC-based coatings, controlled-release platforms, and dietary supplement clean-label formats offered by Roquette Health & Pharma Solutions.
  • JRS Pharma (J. Rettenmaier & Söhne): Specialty excipient manufacturer focused on cellulose-based excipients (MCC, microcrystalline cellulose, croscarmellose sodium, HPMC). Direct competitor in the cellulosic excipient franchise that underpins Roquette Health & Pharma Solutions' pharmaceutical business.
  • Ashland Global Holdings: Specialty chemical company with a significant pharmaceutical excipients and oral solid dose franchise (e.g., cellulosics, coating systems, controlled-release polymers). Direct competitor to IFF/Roquette's HPMC and POLYOX-based offerings for pharma formulation.

Emerging players

  • Tate & Lyle: Specialty food and beverage ingredients company expanding into pharma-grade and clean-label excipients. Adjacent competitor in the dietary supplement and nutraceutical excipient space where Roquette Health & Pharma Solutions operates.
  • Ingredion Incorporated: Specialty ingredient company with growing pharma and nutraceutical excipient lines (e.g., starch-based, clean-label ingredients). Increasingly comparable to Roquette Health & Pharma Solutions' dietary supplement and starch-derived alginate platforms.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Pharma Solutions at IFF social profiles

Digital presence

Pharma Solutions at IFF financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharma Solutions at IFF leadership team

Management profile

Number of profiles

Pharma Solutions at IFF funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharma Solutions at IFF M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Solutions at IFF

What does Pharma Solutions at IFF do?

Pharma Solutions at IFF manufactures and supplies pharmaceutical excipients and specialty polymer ingredients — including cellulosics, seaweed extracts, ultrapure biopolymers, and specialized synthetic polymers — for use in drug formulation, controlled release drug delivery, dietary supplement manufacturing, and biomedical/life science applications. Its proprietary product portfolio encompasses POLYOX™ polyethylene oxide polymers, METHOCEL™ HPMC, METHONOVA™ biopolymers, NovaMatrix® and NovaMatrix-3D™ platforms, starch-derived alginate technologies, and the DS 700 water-resistant capsule.

Is Pharma Solutions at IFF a public or private company?

Pharma Solutions at IFF is a private company. It is classified as corporate owned and is currently acquired.

When was Pharma Solutions at IFF founded?

Pharma Solutions at IFF was founded in -1. It employs 5,001 to 10,000 people.

Where is Pharma Solutions at IFF based?

Pharma Solutions at IFF is headquartered in New York, United States, in the North America region.

How does Pharma Solutions at IFF make money?

Three revenue lines are on record. Pharmaceutical Excipients and Ingredients are the primary driver. The others are biomedical and Biotechnology Solutions and dietary Supplement Ingredients.

Who are Pharma Solutions at IFF's main competitors?

Broad incumbents on record are Evonik Industries, DuPont Nutrition & Biosciences (now part of IFF, but specialty excipient operations continue under separate entities), BASF SE and Merck KGaA Life Science (MilliporeSigma). Direct peers are SPI Pharma, Colorcon, JRS Pharma (J. Rettenmaier & Söhne) and Ashland Global Holdings. Emerging players are Tate & Lyle and Ingredion Incorporated.

Does Pharma Solutions at IFF have an API?

No public API is recorded for Pharma Solutions at IFF.

What industry is Pharma Solutions at IFF in?

Pharma Solutions at IFF's product category is Pharmaceutical Excipients. Its primary akta.pro industry code is IMANABAK, Medical & Food-Contact Specialty Compounds, with a secondary code of IMAEAOAA, Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Canadian Press NewsLMR by IFF Inaugurates New Experimental Field in GrasseLMR Naturals by IFF inaugurated its new experimental field, Domaine des Naturels LMR, in Grasse, France. The 1.8-hectare site supports research on natural species, cultivation, and education, including the LMR Naturals Academy. It builds on IFF's 2000 acquisition and long-term investment in the region.AETOSWireLMR by IFF Inaugurates New Experimental Field in GrasseLMR Naturals by IFF inaugurated its 1.8-hectare experimental field Domaine des Naturels LMR in Grasse, dedicated to natural ingredients research and education. The field maintains endemic species and will host the LMR Naturals Academy, building on IFF's 2000 acquisition.PR NewswireMicrocrystalline Cellulose (MCC) Market to Reach US$ 2.5 Billion Driven by Pharmaceutical Expansion and Functional Food Demand - Persistence Market ResearchThe global microcrystalline cellulose market is projected to grow from US$1,556.9 million in 2025 to US$2,504.6 million by 2032, a CAGR of 7.0%. Europe leads with a 30.8% share, while refined wood pulp accounts for 84.5% of raw material revenue. Roquette's 2025 acquisition of IFF Pharma Solutions strengthens its excipients platform.Personal Care InsightsIn-cosmetics Global 2026: Roquette Beauté releases four formulationsRoquette Beauté launched four new formulations at In-cosmetics Global 2026, with general manager Bénédicte Courel emphasizing sensoriality and efficacy. Three of the innovations are alginate-based technologies derived from starch, made possible by Roquette's recent acquisition of IFF Pharma Solutions, offering enhanced rheology and viscosity impacts. The fourth innovation, DS 700, is a water-resistant capsule with nearly 100% resistance designed for long-lasting beauty applications.GlobeNewswireRoquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environmentRoquette Frères reported full-year 2025 results with turnover of €4,877 million (up 8% nominally but down 5% like-for-like) and Current EBITDA of €612 million (margin of 12.6%, up 54 basis points), reflecting the integration of IFF Pharma Solutions acquired on May 1, 2025. Despite the resilient operational performance in pharmaceutical and food specialties, the company posted a net loss of €265 million, primarily due to €87 million in acquisition and integration costs and €231 million in impairment charges. Excluding the IFF acquisition cash impact, Free Cash-Flow reached €301 million, while net debt stood at €2,390 million with a leverage ratio of 3.48x. Looking ahead, Roquette launched its 'Shift & Lead' strategic plan in early 2026 to reinforce competitiveness and target deleveraging to 2.3x–2.7x by 2027.openPR.comBio-Based Molecule Market Driven by Sustainability Goals and Rising Demand for Biodegradable Alternatives by 2031The global bio-based molecule market reached US$1,336.72 million in 2023 and is projected to reach US$2,437.83 million by 2031, a CAGR of 7.8%. Growth is driven by sustainability goals, regulatory support, and M&A activity, including Roquette's acquisition of IFF Pharma Solutions.GlobeNewswireRoquette Announces a New Organization following the Acquisition of IFF Pharma SolutionsRoquette announced a new organization after acquiring IFF Pharma Solutions, creating two business groups and appointing Isabelle Bouvier as CEO of Health & Pharma Solutions and Pascal Leroy as CEO of Nutrition & Bioindustry. Béatrice Totel replaces Isabelle Bouvier as CFO. The company, with over 11,000 employees and €4.5 billion turnover in 2024, aims to enhance agility and customer responsiveness.GlobeNewswireRoquette Completes the Acquisition of IFF Pharma SolutionsRoquette completed its acquisition of IFF Pharma Solutions, strengthening its position in pharmaceutical excipients. The deal follows the 2023 Qualicaps acquisition and aligns with Roquette's strategy to invest in high-growth markets. CEO Pierre Courduroux said the move positions Roquette as a go-to partner for drug delivery solutions.Stock TitanIFF Unveils Sustainable Pharma Solutions at Excipient World 2025IFF Pharma Solutions will showcase its sustainable pharma portfolio at Excipient World 2025, including controlled-release formulations and nitrosamine risk mitigation solutions. The company will present its METHOCEL, ETHOCEL, and POLYOX products, plus new Low Nitrite METHOCEL and Avicel PH LN, at booth 205. Dr. Anne Adden will deliver a presentation on sustainable excipient design.FinancialContent Business PageIFF Pharma Solutions to Showcase Plant-Based Dietary Supplement Ingredients and Technical Expertise at Vitafoods™ Europe 2025IFF Pharma Solutions will showcase its plant-based dietary supplement ingredients at Vitafoods Europe 2025 in Barcelona, May 20-22, at booth 4F25 in hall 4. The portfolio includes SeaGel, VERDIGEL SC, GRINDSTED Pectin Premium, Avicel, Ac-Di-Sol, METHOCEL, and Accelerate. The company aims to help customers improve formulation and processing for supplements.